Prosecution Insights
Last updated: November 04, 2026
Application No. 17/905,083

DEVICES AND COMPONENTS FOR AUTOMATED TISSUE PROCESSING AND STAINING AND USES THEREOF

Final Rejection §102§103§112§DP
Filed
Aug 26, 2022
Priority
Mar 11, 2020 — nonprovisional of PCTCN2021079901 +5 more
Examiner
CLARKE, TRENT R
Art Unit
1651
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Guizhou Meixinda Medical Technologies Co. Ltd.
OA Round
2 (Final)
42%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
67%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allowance Rate
186 granted / 441 resolved
-17.8% vs TC avg
Strong +25% interview lift
Without
With
+24.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
31 currently pending
Career history
484
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
42.7%
+2.7% vs TC avg
§102
11.6%
-28.4% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 441 resolved cases

Office Action

§102 §103 §112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Application, Amendments, And/Or Claims The Applicants amendments/remarks received 7/1/2026 are acknowledged. Claims 70 and 74 are amended; claims 1-59 and 75 are canceled; claims 60-74 are pending; claims 60-69 are withdrawn; claims 70-74 have been examined on the merits. Drawings The replacement drawings received 7/1/2026 are accepted. Claim Rejections - 35 USC § 112 The rejection of claims 70-75 under 35 U.S.C. § 112(a), as set forth at pp. 4-5 of the previous Office Action, is moot regarding claim 75 due to cancelation of the claim and is withdrawn regarding the remaining claims in view of the amendment of the claims. The rejection of claims 70-75 under 35 U.S.C. § 112(b), as set forth at pp. 5-7 of the previous Office Action, is moot regarding claim 75 due to cancelation of the claim and is withdrawn regarding the remaining claims in view of the amendment of the claims. Claim Rejections - 35 USC § 102 The rejection of claims 70-74 under 35 U.S.C. 102(a)(1)/102(a)(2) over Copeland et al., US 5595707 (cite A, PTO-892, 1/14/2026; herein “Copeland”) as set forth at pp. 7-9 of the previous Office Action, is withdrawn in view of the amendment of the claims. Claim Rejections - 35 USC § 103 The rejection of claims 70-75 under 35 U.S.C. 103 over Copeland et al., US 5595707 (cite A, PTO-892, 1/14/2026; herein “Copeland”) in view of Zhang et al., CN208092056 (Foreign Patent Document cite 6, IDS, 8/30/2022; English language translation from Espacenet (cite U, PTO-892, 1/14/2026; herein “Zhang”)) as set forth at pp. 9-12 of the previous Office Action, is moot regarding claim 75 due to cancelation of the claim and is withdrawn regarding the remaining claims in view of the amendment of the claims. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 70-74 are rejected under 35 U.S.C. 103 as being unpatentable over Copeland et al., US 5595707 (cite A, PTO-892, 1/14/2026; herein “Copeland”) in view of Zhang et al., CN208092056 (Foreign Patent Document cite 6, IDS, 8/30/2022; English language translation from Espacenet (cite U, PTO-892, 1/14/2026; herein “Zhang”) is referenced in the cites below) and Ng, US 2020/0319067 (cite A, attached PTO-892; herein “Ng”). Copeland teaches an automated immunostaining apparatus and methods of use for the apparatus (Abst.) wherein the apparatus comprises a microscope slide carousel (24 in Fig. 1; col. 6, l. 20 - col. 7, l. 9), wherein the microscope slide carousel is configured to rotate on a first axis of rotation (Fig. 1; col. 6, l. 20 - col. 7, l. 9), and wherein the microscope slide carousel comprises at least one microscope slide cartridge stall (26 in Fig. 1); a reagent assembly comprising: (i) a reagent carousel (10 in Fig. 1; col. 6, l. 20 - col. 7, l. 9), wherein the reagent carousel is configured to rotate on a second axis of rotation (Fig. 1; col. 6, l. 20 - col. 7, l. 9), and wherein the reagent carousel comprises at least one reagent holder (holes in 10 in Fig. 1), (ii) a dispensing actuator (18 in Fig. 1), and wherein the reagent carousel is positioned above the microscope slide carousel, and where the reagent carousel and the microscope slide carousel are positioned such that when a reagent is placed in the reagent carousel the reagent can flow from the reagent carousel to the microscope slide carousel (Fig. 1; col. 6, l. 20 - col. 7, l. 9), wherein the microscope slide cartridge assembly is interfaced with a microscope slide comprising the tissue sample (26 in Fig. 1; col. 6, l. 20 - col. 7, l. 9; Fig. 5; col. 7, l. 55 - col. 8, l. 19). Copeland teaches methods of staining a tissue sample comprising placing a microscope slide cartridge assembly (26) in a microscope slide stall of a tissue staining device (Fig. 1; col. 6, l. 20 - col. 7, l. 9; Fig. 5; col. 7, l. 55 - col. 8, l. 19) and initiating the tissue staining device to perform a tissue staining protocol thereby staining the tissue sample (col. 6, ll. 20-32; col. 2, l. 66 - col. 3, l. 7; col. 19, l. 49 - col. 21, l. 11). Copeland teaches that the staining protocol is selected (col. 6, ll. 20-32; col. 2, l. 66 - col. 3, l. 7). Copeland teaches that the tissue staining protocol can comprise a chemical staining protocol or an immunohistochemical staining protocol (col. 2, ll. 28-38; col. 6, ll. 20-32). Copeland teaches that the method further comprises the step of mounting a covertile to the microscope slide after performing the tissue staining protocol (col. 6, ll. 21-28). Copeland clearly teaches that the tissue staining protocol comprises dispensing a reagent from the reagent carousel to the microscope slide, followed by vortex mixing stations to ensure the reagent fully coats the tissue sample, followed by rinsing the slide with rinse solution, i.e., washing with wash solution, in the rinse station (Fig. 12; col. 9, l. 57 - col. 10, l. 40), i.e., from a common liquid dispenser, and removing the wash solution by a jet drain (col. 19, l. 49 - col. 21, l. 11; col. 24, ll. 31-46) wherein the wash solution is evacuated through a waste removal outlet of the microscope slide carousel via a waste flow element (Fig. 13; col. 9, l. 57 - col. 10, l. 40) wherein the wash solution can comprise a buffer (col. 24, ll. 43-46). Hence, Copeland’s method differs from claim 70, inter alia, because Copeland’s microscope slide cartridge assembly does not comprise a microscope slide cartridge that interfaces with a microscope slide comprising the tissue sample, wherein the microscope slide cartridge comprises a gasket, a clip configured to hold the microscope slide cartridge against a surface of the microscope slide so that the gasket seals around the tissue sample on the microscope slide to form a chamber over the tissue sample, and an inclined waste flow pathway configured to direct fluid flow from the chamber to a waste output element. However, a person of ordinary skill in the art at the time of filing would have found it obvious for the microscope slide cartridge assembly in the method made obvious by Copeland to comprise a microscope slide cartridge that interfaces with a microscope slide comprising the tissue sample, wherein the microscope slide cartridge comprises a gasket, a clip configured to hold the microscope slide cartridge against a surface of the microscope slide so that the gasket seals around the tissue sample on the microscope slide to form a chamber over the tissue sample, and an inclined waste flow pathway configured to direct fluid flow from the chamber to a waste output element in view of the disclosure of Ng. Ng teaches a microscope slide cartridge assembly for sample processing that interfaces with a microscope slide comprising the tissue sample (Abst.; [0009-10]), wherein the microscope slide cartridge comprises a gasket ([0028]; Figs. 18-19, 2200), a clip configured to hold the microscope slide cartridge against a surface of the microscope slide so that the gasket seals around the tissue sample on the microscope slide to form a chamber over the tissue sample ([0025], [0028]; Fig. 2, 2160), and an inclined waste flow pathway configured to direct fluid flow from the chamber to a waste output element ([0072]; Fig. 5, 1500). Ng teaches that their microscope slide cartridge assembly is superior to prior microscope slide cartridge assemblies [0005-7]; hence, a person of ordinary skill in the art at the time of filing would have found it obvious to practice Copeland’s method wherein the microscope slide cartridge assembly interfaces with a microscope slide comprising the tissue sample, wherein the microscope slide cartridge comprises a gasket, a clip configured to hold the microscope slide cartridge against a surface of the microscope slide so that the gasket seals around the tissue sample on the microscope slide to form a chamber over the tissue sample and an inclined waste flow pathway configured to direct fluid flow from the chamber to a waste output element. The method made obvious by Copeland in view of Ng differs from claim 70 in that Copeland does not rotate the microscope slide carousel such that the reagent fully coats the tissue sample nor rotate the microscope slide carousel to remove the wash solution; however, a person of ordinary skill in the art at the time of filing would have found it obvious to practice Copeland’s method wherein the liquids are distributed and removed from the slides by rotation of the slide carousel in view of Zhang. Zhang teaches a slide immunostaining apparatus comprising a slide carousel wherein the reagent is tiled across the slide, i.e., coats the slide, by centrifugally rotating the carousel (Abst.; “DETAILED DESCRIPTION OF THE EMBODIMENTS”, ¶2) and cleaning solution, i.e., wash solution, is distributed across the slide and into a waste liquid port by centrifugal rotation (pdf p. 6, “Working Principle”). Hence, a person of ordinary skill in the art at the time of filing would have found it obvious to modify the tissue staining device made obvious by Copeland and Ng to practice the method of Zhang wherein the coating of the tissue samples and washing of the tissue samples is facilitated by centrifugally rotating the carousel; therefore, claims 70-74 are prima facie obvious. Response to Arguments Applicant's arguments filed 7/1/2026 have been fully considered but they are not persuasive. Arguments of the Applicant’s Response on pp. 7-13 regarding the objection to the drawings and rejections under 35 U.S.C. § 112(a), 112(b), 102(a)(1)l(a)(2) and 103 are moot as the rejections have been withdrawn. Applicant argues that Copeland in view of Zhang does not teach the amended claims (pp. 8-13). However, Copeland in view of Ng and Zhang make obvious the method set forth in claims 70-74 as discussed in the rejection above. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 70-74 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 76, 86-87, 110, 112-113 and 115 of copending Application No. 17198058 (herein “’058”) in view of Copeland. Claim 76 of ‘058 recites a tissue staining device comprising: (a) a microscope slide carousel having an outer perimeter, wherein the microscope slide carousel is configured to rotate on a first axis of rotation controlled by a first rotary control mechanism, and wherein the microscope slide carousel comprises at least one microscope slide cartridge stall configured to hold a microscope slide cartridge assembly, and (b) a reagent assembly comprising: (i) a reagent carousel, wherein the reagent carousel is configured to rotate on a second axis of rotation that is not coaxial with the first axis of rotation and wherein the second axis of rotation is located outside the outer perimeter of the microscope slide carousel, and wherein the reagent carousel comprises at least one reagent holder, (ii) a dispensing actuator, and wherein the reagent carousel is positioned above the microscope slide carousel, and wherein the reagent carousel and the microscope slide carousel are positioned such that when a reagent is placed in the reagent carousel the reagent can flow from the reagent carousel to the microscope slide carousel, wherein the reagent assembly further comprises a second rotary control mechanism comprising a stationary actuator positioned relative to the second axis of rotation, and wherein fluid is removed from a chamber of the microscope slide cartridge assembly by centrifugal force; claim 86 of ‘058 recites the tissue staining device of claim 76, further comprising the microscope slide cartridge assembly; claim 87 of ‘058 recites the tissue staining device of claim 86, wherein the microscope slide cartridge assembly comprises: (a) fluid input port positioned on a top side of the microscope slide cartridge assembly; (b) a gasket positioned on a bottom side of the microscope slide cartridge assembly, wherein the gasket is configured to form a sealed perimeter on a face of a microscope slide; (c) one or more walls, wherein the one or more walls are configured to connect, at least in part, the top side and the gasket thereby forming a chamber over a face of the microscope slide; (d) one or more clips configured to hold the face of the microscope slide against the gasket; (e) a portion of a locking clip; (f) an inclined waste flow pathway configured to direct fluid flow from the chamber to a waste output element; and (g) a microscope slide; claim 110 of ‘058 recites the tissue staining device of claim 76, wherein the reagent assembly comprises at least one common liquid dispenser comprising a liquid dispenser output port and at least one liquid pump, wherein the liquid dispenser output port is positioned such that when a liquid is dispensed from the liquid dispenser output port the liquid can flow from the liquid dispenser output port to the input port of the microscope slide cartridge assembly on the microscope slide carousel, wherein the directionality of the flow of the liquid is based on that of gravitational force, wherein the liquid flow represents an imaginary liquid dispensing axis, and wherein the liquid dispensing axis, the first axis of rotation, and the second axis of rotation are substantially parallel; claim 112 of ‘058 recites the tissue staining device of claim 76, further comprising a control unit; claim 113 of ‘058 recites the tissue staining device of claim 112, wherein the control unit comprises one or more processors and memory storing one or more programs, the one or more programs configured to be executed by the one or more processors, the one or more programs including instructions for: (i) positioning the reagent carousel and/or positioning the microscope slide carousel; (ii) enacting the dispensing actuator; and (iii) performing a tissue staining protocol and/or performing a tissue dehydration protocol; and claim 115 of ‘058 recites the tissue staining device of claim 76, wherein the microscope slide carousel is configured to control rotary motions back and forth to agitate fluid in microscope slide cartridges to achieve mixing reagents and thoroughly wash clean the tissues on the slides. Hence, a person of ordinary skill in the art at the time of filing would have found it obvious to practice a method of staining a tissue sample comprising the steps of (a) placing a microscope slide cartridge assembly in a microscope slide stall of the tissue staining device recited in ‘058, wherein the microscope slide cartridge assembly comprises a microscope slide cartridge that interfaces with a microscope slide comprising the tissue sample, wherein the microscope slide cartridge comprises a gasket, a clip configured to hold the microscope slide cartridge against a surface of the microscope slide so that the gasket seals around the tissue sample on the microscope slide to form a chamber over the tissue sample, and an inclined waste flow pathway configured to direct fluid flow from the chamber to a waste output element, and (b) initiating the tissue staining device to perform a tissue staining protocol thereby staining the tissue sample wherein the method comprises mounting a microscope slide to the apparatus, dispensing a reagent from the reagent carousel to the microscope slide, rotating the microscope slide carousel such that the reagent fully coats the tissue sample, dispensing a wash buffer from the common liquid dispenser to the microscope slide; and rotating the microscope slide carousel such that a solution comprising the wash buffer is moved to the waste removal outlet of the microscope slide carousel via the waste flow element; therefore, instant claims 70 and 74 are prima facie obvious over the claims of ‘058. The claims of ‘058 do not specifically teach selecting a tissue staining protocol wherein the tissue staining protocol comprises a chemical staining protocol or an immunohistochemical staining protocol; however, a person of ordinary skill in the art at the time of filing would have found it obvious to select a tissue staining protocol wherein the tissue staining protocol comprises a chemical staining protocol or an immunohistochemical staining protocol in view of the disclosure of Copeland. Copeland teaches an automated immunostaining apparatus and methods of use for the apparatus (Abst.). Copeland teaches methods of staining a tissue sample comprising placing a microscope slide cartridge assembly (26) in a microscope slide stall of a tissue staining device (Fig. 1; col. 6, l. 20 - col. 7, l. 9; Fig. 5; col. 7, l. 55 - col. 8, l. 19) and initiating the tissue staining device to perform a tissue staining protocol thereby staining the tissue sample (col. 6, ll. 20-32; col. 2, l. 66 - col. 3, l. 7; col. 19, l. 49 - col. 21, l. 11). Copeland teaches that the staining protocol is selected (col. 6, ll. 20-32; col. 2, l. 66 - col. 3, l. 7). Copeland teaches that the tissue staining protocol can comprise a chemical staining protocol or an immunohistochemical staining protocol (col. 2, ll. 28-38; col. 6, ll. 20-32). Hence, instant claims 71-73 are prima facie obvious over the claims of ‘058 in view of Copeland. This is a provisional nonstatutory double patenting rejection. Response to Arguments Applicant acknowledges the rejection and indicates that a terminal disclaimer will be filed at such time as the claims are otherwise allowable. The rejection is maintained with modification to address claim amendments. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Trent R Clarke whose telephone number is (571)272-2904. The examiner can normally be reached M-F 10-7 MST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melenie Gordon can be reached at 571-272-8037. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TRENT R CLARKE/ Examiner, Art Unit 1651 /DAVID W BERKE-SCHLESSEL/ Primary Examiner, Art Unit 1651
Read full office action

Prosecution Timeline

Aug 26, 2022
Application Filed
Jan 14, 2026
Non-Final Rejection mailed — §102, §103, §112
Jul 01, 2026
Response Filed
Sep 25, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781168
INTEGRATED SYSTEM FOR MULTIPLE CULTIVATIONS OF A BIOLOGICAL AGENT AND METHODS OF USE THEREOF
3y 0m to grant Granted Nov 03, 2026
Patent 12751737
Method for Surgical Treatment of Ovary
3y 8m to grant Granted Oct 06, 2026
Patent 12736527
FUNCTIONAL CORTICAL ORGANOIDS, METHODS OF MAKING, AND USES THEREOF
2y 11m to grant Granted Sep 15, 2026
Patent 12692472
GLYCOENGINEERING USING LEISHMANIA CELLS
4y 0m to grant Granted Jul 28, 2026
Patent 12686884
COMPOSITIONS, SYSTEMS AND METHODS FOR CRISPR-BASED ENZYME OPTIMIZATION
3y 2m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
42%
Grant Probability
67%
With Interview (+24.7%)
3y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 441 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month